



31 March 2021

Company Announcements Office
Australian Securities Exchange
Exchange Centre
20 Bridge Street
Sydney, NSW 2000

New CFO appointed and key staff hired to drive Northern Hemisphere Business Development

Medlab (ASX.MDC), an Australian biotech using delivery platforms to enhance medicines particularly in the field of oncology, today announces appointments to drive business development and partnering initiatives in the Northern Hemisphere.

The Company has appointed Mr Naresh Patel as Global Business Development Manager and Mr Robert Jensen as Medical Science Liaison (MSL) in the USA.

Mr Patel will explore partnering/licensing opportunities, with a particular emphasis on opportunities in the Northern Hemisphere. He is an experienced Business Development professional who joins Medlab from Clarity Global Group, a leading pharmaceutical distributor who specialise in commercial activities, logistics and marketing.

Mr Jensen will work with Medlab in the USA to advance compassionate access to NanaBis™ via an Expanded Access Investigational New Drug pathway (EA-IND). Mr Jensen is a registered pharmacist and has extensive experience in retail pharmacy. In his previous role Mr Jensen was Pharmacy Manager with CVS Pharmacy, the largest pharmacy chain in the US by number of locations and total prescription revenue. He is currently studying clinical Cannabinoid Pharmacy Certificate (CCPC) through the International Society of Cannabis Pharmacists (ISCPH).

Medlab also advises that Mr Alan Dworkin has resigned as CFO & Company Secretary, effective from 1 April 2021. Alan has served as Chief Financial Officer of Medlab since 2015. During this time he has made a valuable contribution to the company's management and leadership team.

The Company has commenced recruiting for an experienced Chief Financial Officer with proven healthcare experience, a focus on northern hemisphere expansion, market access with a pharmaceutical focus. In the interim, the Company advises that Mr Simon Allsop, iKeep Bookkeeping Pty Ltd, has been appointed as CFO and Drew Townsend has been appointed Company Secretary.

Simon started his career at KPMG Sydney in 2000. After seven years at KPMG Simon saw an opportunity to start his own firm, growing it to a team of 50. In late 2016 he sold that business and started iKeep in January 2020. Simon has a dedicated team of national Financial Advisors who works one-on-one with business owners and their management teams.

"I would like to take this opportunity to thank Alan for his service and commitment to Medlab at a time that has seen us significantly advance our clinical programs and partnering activities. We wish him all the best in the future, and welcome Simon onboard as CFO in the interim."

"I would also like to welcome Mr Patel and Mr Jensen who both bring an exceptional combination of talent and expertise in business development and partnering. These appointments will be instrumental to our US and UK clinical and commercial pathway, including establishing US NanaBis sales under the FDA's Expanded Access program, supporting our Phase III study for cancer bone pain and advancing NanoCelle partnering and licensing," Dr Sean Hall said.

ENDS

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

About Medlab – www.medlab.co

Medlab Clinical is an Australian-based, ASX listed biotech using delivery platforms to enhance medicines, particularly in the field of oncology. In pain management, Medlab is developing cannabis-based medicines. Its lead candidate NanaBis™ equimolar comprising of THC: CBD, is being developed as non-opioid alternative for the treatment of cancer-induced bone pain and has IND approval to enter Phase III clinical trials.

Medlab’s proprietary drug delivery platform NanoCelle® is used to enhance a wide range of active ingredients, with commercial opportunities in pharmaceuticals, generic medicines, cosmetics, nutraceuticals, and textiles. Medlab’s products are proudly validated by research and supported by a growing patent portfolio. Our team of scientists, researchers and doctors are dedicated to building products that are scientifically optimised to deliver more for human health and beyond.

For further information contact:

Dr Sean Hall, CEO Medlab Clinical T: + 61 2 8203 9520 - sean_hall@medlab.co	Kyahn Williamson, WE Communications T: + 61 0401018828 - kwilliamson@we-worldwide.com
---	--